NZ521183A - Crystalline form of lopinavir - Google Patents
Crystalline form of lopinavirInfo
- Publication number
- NZ521183A NZ521183A NZ521183A NZ52118301A NZ521183A NZ 521183 A NZ521183 A NZ 521183A NZ 521183 A NZ521183 A NZ 521183A NZ 52118301 A NZ52118301 A NZ 52118301A NZ 521183 A NZ521183 A NZ 521183A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lopinavir
- solid state
- peak
- range
- infrared spectrum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53825700A | 2000-03-30 | 2000-03-30 | |
| US09/793,536 US6608198B2 (en) | 2000-03-30 | 2001-02-27 | Crystalline pharmaceutical |
| PCT/US2001/009112 WO2001074787A2 (en) | 2000-03-30 | 2001-03-21 | Crystalline pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ521183A true NZ521183A (en) | 2004-03-26 |
Family
ID=27065762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ521183A NZ521183A (en) | 2000-03-30 | 2001-03-21 | Crystalline form of lopinavir |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1268442A2 (ko) |
| JP (1) | JP2003529592A (ko) |
| KR (1) | KR100773258B1 (ko) |
| CN (2) | CN1330639C (ko) |
| AR (2) | AR033360A1 (ko) |
| AU (3) | AU2001250920B2 (ko) |
| BG (1) | BG107165A (ko) |
| BR (1) | BR0109433A (ko) |
| CA (1) | CA2403635A1 (ko) |
| CZ (1) | CZ20023529A3 (ko) |
| HU (1) | HUP0302675A3 (ko) |
| IL (1) | IL151551A0 (ko) |
| MX (1) | MXPA02009559A (ko) |
| MY (1) | MY128296A (ko) |
| NO (1) | NO325005B1 (ko) |
| NZ (1) | NZ521183A (ko) |
| PE (1) | PE20011232A1 (ko) |
| PL (1) | PL359727A1 (ko) |
| SA (2) | SA06270303B1 (ko) |
| SK (1) | SK14832002A3 (ko) |
| TW (1) | TWI284640B (ko) |
| WO (1) | WO2001074787A2 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| WO2010089753A2 (en) * | 2009-02-06 | 2010-08-12 | Hetero Research Foundation | Novel polymorphs of lopinavir |
| WO2011025849A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis c virus |
| CN112830899A (zh) * | 2021-01-18 | 2021-05-25 | 合肥华方医药科技有限公司 | 一种洛匹那韦新晶型及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO1998057648A1 (en) * | 1997-06-16 | 1998-12-23 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
-
2001
- 2001-03-07 MY MYPI20011034A patent/MY128296A/en unknown
- 2001-03-21 PL PL35972701A patent/PL359727A1/xx not_active Application Discontinuation
- 2001-03-21 AU AU2001250920A patent/AU2001250920B2/en not_active Revoked
- 2001-03-21 CN CNB018076882A patent/CN1330639C/zh not_active Expired - Lifetime
- 2001-03-21 HU HU0302675A patent/HUP0302675A3/hu unknown
- 2001-03-21 CA CA002403635A patent/CA2403635A1/en not_active Abandoned
- 2001-03-21 CN CNA2007101123988A patent/CN101066952A/zh active Pending
- 2001-03-21 CZ CZ20023529A patent/CZ20023529A3/cs unknown
- 2001-03-21 KR KR1020027012849A patent/KR100773258B1/ko active IP Right Grant
- 2001-03-21 MX MXPA02009559A patent/MXPA02009559A/es active IP Right Grant
- 2001-03-21 EP EP01924250A patent/EP1268442A2/en not_active Withdrawn
- 2001-03-21 IL IL15155101A patent/IL151551A0/xx unknown
- 2001-03-21 JP JP2001572482A patent/JP2003529592A/ja active Pending
- 2001-03-21 BR BR0109433-5A patent/BR0109433A/pt not_active Application Discontinuation
- 2001-03-21 NZ NZ521183A patent/NZ521183A/en not_active IP Right Cessation
- 2001-03-21 WO PCT/US2001/009112 patent/WO2001074787A2/en active IP Right Grant
- 2001-03-21 SK SK1483-2002A patent/SK14832002A3/sk not_active Application Discontinuation
- 2001-03-21 AU AU5092001A patent/AU5092001A/xx active Pending
- 2001-03-29 AR ARP010101522A patent/AR033360A1/es not_active Application Discontinuation
- 2001-03-30 PE PE2001000299A patent/PE20011232A1/es not_active Application Discontinuation
- 2001-05-02 TW TW090107717A patent/TWI284640B/zh active
- 2001-08-07 SA SA06270303A patent/SA06270303B1/ar unknown
- 2001-08-07 SA SA01220270A patent/SA01220270B1/ar unknown
-
2002
- 2002-09-30 NO NO20024679A patent/NO325005B1/no not_active Application Discontinuation
- 2002-10-03 BG BG107165A patent/BG107165A/bg unknown
-
2005
- 2005-06-29 AR ARP050102702A patent/AR049560A2/es unknown
-
2006
- 2006-09-27 AU AU2006222711A patent/AU2006222711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003529592A (ja) | 2003-10-07 |
| SA06270303B1 (ar) | 2009-08-02 |
| TWI284640B (en) | 2007-08-01 |
| HUP0302675A2 (hu) | 2003-12-29 |
| KR100773258B1 (ko) | 2007-11-05 |
| KR20030011807A (ko) | 2003-02-11 |
| WO2001074787A2 (en) | 2001-10-11 |
| NO20024679D0 (no) | 2002-09-30 |
| AU5092001A (en) | 2001-10-15 |
| AU2001250920B2 (en) | 2006-06-29 |
| CN101066952A (zh) | 2007-11-07 |
| PL359727A1 (en) | 2004-09-06 |
| WO2001074787A3 (en) | 2002-02-07 |
| NO325005B1 (no) | 2008-01-14 |
| AU2006222711A1 (en) | 2006-10-19 |
| BR0109433A (pt) | 2004-08-10 |
| AR049560A2 (es) | 2006-08-16 |
| SK14832002A3 (sk) | 2003-02-04 |
| PE20011232A1 (es) | 2001-12-08 |
| MY128296A (en) | 2007-01-31 |
| AR033360A1 (es) | 2003-12-17 |
| CN1330639C (zh) | 2007-08-08 |
| HUP0302675A3 (en) | 2004-03-29 |
| CA2403635A1 (en) | 2001-10-11 |
| IL151551A0 (en) | 2003-04-10 |
| EP1268442A2 (en) | 2003-01-02 |
| MXPA02009559A (es) | 2003-05-21 |
| SA01220270B1 (ar) | 2006-11-14 |
| NO20024679L (no) | 2002-09-30 |
| CN1422259A (zh) | 2003-06-04 |
| BG107165A (bg) | 2003-07-31 |
| CZ20023529A3 (cs) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8058433B2 (en) | Crystalline pharmaceutical | |
| US8884013B2 (en) | Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof | |
| TW200944508A (en) | Novel solid forms of bendamustine hydrochloride | |
| HUE028620T2 (en) | Tetrahydroisoquinoline derivative salt and solvates | |
| AU2006222711A1 (en) | Crystalline pharmaceutical | |
| AU2001250920A1 (en) | Crystalline pharmaceutical | |
| CN112094249B (zh) | 磺胺甲噻二唑-糖精共晶及其制备方法与应用 | |
| CN106565699B (zh) | 一种艾沙康唑硫酸盐晶体及其制备方法 | |
| ZA200206962B (en) | Crystalline pharmaceutical. | |
| AU767331B2 (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo(2.2.2) oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as NK-1 receptor antagonists | |
| KR20120060947A (ko) | 신규 고체 물질 ｛［（2ｓ,5ｒ,8ｓ,11ｓ）-5-벤질-11-（3-구아니디노-프로필）-8-이소프로필-7-메틸-3,6,9,12,15-펜타옥소-1,4,7,10,13-펜타아자-시클로펜타데크-2-일］-아세트산｝ 및 이의 제조 방법 | |
| US11999750B2 (en) | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide | |
| WO2023139313A1 (en) | Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist | |
| CN105612160A (zh) | 用作半胱氨酸蛋白酶抑制剂的N-[1-6-(乙炔基-3-氧代-六氢-呋喃并[3,2-b]吡咯-4-羰基)-3-甲基-丁基]-4-[5-氟-2-(4-甲基-哌嗪基)噻唑-4-基]-苯甲酰胺的盐的形式2结晶多晶型物 | |
| JP2021525230A (ja) | ４−フェニルチアゾール誘導体の結晶形およびその調製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 21 MAR 2021 BY THOMSON REUTERS Effective date: 20131218 |
|
| ASS | Change of ownership |
Owner name: ABBVIE INC., US Effective date: 20140327 |
|
| S43A | Offer to surrender | ||
| S43 | Surrender of patents according section 43 patents act |
Effective date: 20200624 |